Dinitramine

Synonyms: 敌乐胺
Dinitramine 是一种除草剂,可激活睾丸细胞中的 Erk/P38/JNK/MAPK 通路并使其中的 PI3k/Akt 通路失活,诱导睾丸细胞发生内质网应激、胞质及线粒体内钙稳态失调、细胞凋亡以及细胞周期基因表达下调,降低睾丸细胞的活力与增殖能力,并通过抑制微管蛋白合成来阻碍细胞分裂,还可诱导斑马鱼胚胎出现心脏发育异常、血管生成受抑、炎症反应、细胞凋亡及胚胎生长受损。
产品编号: MS-V24651 CAS No.: 29091-05-2 分子式: C11H13F3N4O4 分子量: 322.24
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Dinitramine 是一种除草剂,可激活睾丸细胞中的 Erk/P38/JNK/MAPK 通路并使其中的 PI3k/Akt 通路失活,诱导睾丸细胞发生内质网应激、胞质及线粒体内钙稳态失调、细胞凋亡以及细胞周期基因表达下调,降低睾丸细胞的活力与增殖能力,并通过抑制微管蛋白合成来阻碍细胞分裂,还可诱导斑马鱼胚胎出现心脏发育异常、血管生成受抑、炎症反应、细胞凋亡及胚胎生长受损。

生物实验数据

生物活性 Dinitramine is a herbicide that activates the Erk/P38/JNK/MAPK pathway and inactivates the PI3k/Akt pathway in testicular cells, induces endoplasmic reticulum stress, dysregulation of cytosolic and mitochondrial calcium homeostasis, apoptosis, and downregulation of cell cycle gene expression in testicular cells, reduces the viability and proliferative capacity of testicular cells, and impedes cell division by inhibiting tubulin synthesis, and also induces cardiac developmental abnormalities, suppressed angiogenesis, inflammatory responses, apoptosis, and impaired embryonic growth in zebrafish embryos.
体外研究
(In Vitro)

Dinitramine (2-20 μM; 24 h) 降低 TM3 和 TM4 细胞的活力与增殖潜能,其中 20 μM 处理可使 TM3 细胞活力降至 78.7%、TM4 细胞活力降至 84.7%,并使两种细胞系的增殖潜能均降至 50%以下。
Dinitramine (10-20 μM; 6 days) 可降低 3D 培养体系中 TM3 和 TM4 细胞的球状体密度与面积;其中 20 μM 处理可使 TM3 细胞球状体密度降低 22%、面积降低 12%,而 10 μM 和 20 μM 处理均可显著降低 TM4 细胞球状体的密度与面积。
Dinitramine (0-20 μM; 24 h) 可诱导 TM3 和 TM4 细胞发生细胞周期阻滞与细胞死亡,抑制细胞中细胞周期进展基因 Ccnd1、Cdk4 和 Ccne1 的 mRNA 表达,激活细胞中的内质网应激。
Dinitramine (0-20 μM) 升高 TM3 和 TM4 细胞的胞浆及线粒体基质钙水平;20 μM 处理可使 TM3 细胞的胞浆钙水平升高至 230%、TM4 细胞升高至 300%,同时使两种细胞系的线粒体基质钙水平均升高至 230%。
Dinitramine (5-20 μM; 30 min) 可激活 Mapk 信号通路,并使 TM3 和 TM4 细胞中的 Pi3k/Akt 信号通路失活;在两种细胞系中,20 μM 处理 30 min 均可上调磷酸化 Erk1/2、P38 和 Jnk 的水平,同时下调磷酸化 Akt 和 Rps6kb1 的水平。
Dinitramine (20 μM; 24 h) 与钙调节剂联合处理可恢复经 dinitramine 处理的 TM4 细胞的增殖潜能,但无法恢复 TM3 细胞的增殖潜能。

Cell Viability Assay

Cell Line: immature murine Leydig (TM3) cells, immature murine Sertoli (TM4) cells
Concentration: 0, 2, 5, 10, and 20 μM
Incubation Time: 24 h
Result: Reduced relative viability of TM3 cells to 78.7% and TM4 cells to 84.7% at 20 μM.
Reduced relative proliferative potential of TM3 and TM4 cells in a concentration-dependent manner to below 50% at 20 μM.

Cell Cycle Analysis

Cell Line: immature murine Leydig (TM3) cells, immature murine Sertoli (TM4) cells
Concentration: 0, 2, 5, 10, and 20 μM
Incubation Time: 24 h
Result: Increased the number of TM3 and TM4 cells in the sub-G1 phase by approximately 2-fold compared to vehicle controls.
Reduced the number of TM4 cells in the G0/G1 phase by approximately 10%, with no remarkable changes in TM3 cell cycle phase distribution.

Real Time qPCR

Cell Line: immature murine Leydig (TM3) cells, immature murine Sertoli (TM4) cells
Concentration: 20 μM
Incubation Time: 24 h
Result: Significantly reduced the expression of cell cycle progression-related genes Ccnd1, Cdk4, and Ccne1 in both TM3 and TM4 cells.

Western Blot Analysis

Cell Line: immature murine Leydig (TM3) cells, immature murine Sertoli (TM4) cells
Concentration: 0, 5, 10, and 20 μM
Incubation Time: 24 h
Result: Increased Grp78/Bip protein expression in TM3 and TM4 cells in a concentration-dependent manner.
Increased Ire1α protein levels by 1.5-fold in TM3 and 2.4-fold in TM4 cells at 20 μM.
Increased phosphorylated Eif2α levels by 2.3-fold in TM3 and 1.4-fold in TM4 cells at 20 μM.
Increased Chop protein levels by 2.3-fold in TM3 and 2-fold in TM4 cells at 20 μM.

Western Blot Analysis

Cell Line: immature murine Leydig (TM3) cells, immature murine Sertoli (TM4) cells
Concentration: 5-20 μM
Incubation Time: 30 min
Result: Increased phosphorylated Erk1/2 levels to 1.7-fold in TM3 and 1.9-fold in TM4 cells at 20 μM.
Increased phosphorylated P38 and Jnk levels significantly in both cell lines at 20 μM.
Reduced phosphorylated Akt levels to approximately half in TM3 cells and to 0.75-fold in TM4 cells at 20 μM.
Reduced phosphorylated Rps6kb1 levels to approximately half in TM3 cells and 0.59-fold in TM4 cells at 20 μM.
Reduced phosphorylated Rps6 levels to approximately half in TM3 cells (no significant change in TM4 cells) at 20 μM.

Cell Proliferation Assay

Cell Line: immature murine Leydig (TM3) cells, immature murine Sertoli (TM4) cells
Concentration: 20 μM
Incubation Time: 24 h
Result: Restored proliferative potential of TM4 cells by approximately 20% compared to dinitramine alone when co-treated with 1 μM 2-APB.
Restored proliferative potential of TM4 cells to 65% compared to dinitramine alone when co-treated with 2 μM BAPTA.
Did not alter proliferative potential of dinitramine-treated TM3 cells with co-treatment.
体内研究
(In Vivo)

Dinitramine (1.6-6.4 mg/L;水体浸泡;96 小时) 会在 Danio rerio (斑马鱼) 胚胎中诱导浓度依赖性的发育毒性、心脏毒性、血管损伤、炎症以及细胞凋亡。

Animal Model: wild-type; fli1:eGFP transgenic
Dosage: 1.6 mg/L; 3.2 mg/L; 6.4 mg/L
Administration: aqueous immersion; continuous exposure for 96 hours, medium refreshed every 24 hours
Result: Induced concentration-dependent malformations including shortened body length, reduced eye size, spinal curvature, swollen yolk sacs, and pericardial edema; increased pericardial edema to over 300% of control levels at 6.4 mg/L.
Reduced hatchability dose-dependently, reaching near 0% at 6.4 mg/L.
Decreased heart rate dose-dependently to 80 beats per minute at 6.4 mg/L (down from 184 bpm in controls); caused 3-fold enlargement of atrial long-axis diameter at 6.4 mg/L; significantly downregulated cardiac development genes (spaw, bmp4, bmp2b, erbb4b, myh6, itga5, lmna, actc1a, actc2) across all doses.
Reduced caudal vein plexus area to 80% of control and fluorescent intensity to 75% of control at 6.4 mg/L; caused abnormal formation of intersegmental vessels, dorsal longitudinal anastomotic vessel, dorsal aorta, and caudal vein; dysregulated expression of angiogenesis-related genes (kdr, vegfd, flt1, vegfaa).
Significantly upregulated inflammatory genes (il1b, nos2a, il6, tnfa, cox2a, cox2b) at 6.4 mg/L, with il1b expression increased 39-fold compared to controls.
Increased relative apoptotic cell numbers 4.8-fold (eye), 6.4-fold (brain), and 2.7-fold (tail) at 6.4 mg/L; upregulated pro-apoptotic genes (p53, casp8, casp9, casp3) and downregulated anti-apoptotic gene bcl2 across all doses.

化学信息

分子量 322.24
分子式 C11H13F3N4O4
CAS No. 29091-05-2
别名 敌乐胺

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础